DIAMEDICA THERAPEUTICS INC (DMAC)

CA25253X2077 - Common Stock

2.53  -0.06 (-2.32%)

Fundamental Rating

2

Taking everything into account, DMAC scores 2 out of 10 in our fundamental rating. DMAC was compared to 588 industry peers in the Biotechnology industry. While DMAC seems to be doing ok healthwise, there are quite some concerns on its profitability. DMAC has a expensive valuation and it also scores bad on growth.



1

1. Profitability

1.1 Basic Checks

In the past year DMAC has reported negative net income.
In the past year DMAC has reported a negative cash flow from operations.
DMAC had negative earnings in each of the past 5 years.
In the past 5 years DMAC always reported negative operating cash flow.

1.2 Ratios

DMAC has a better Return On Assets (-35.78%) than 65.36% of its industry peers.
The Return On Equity of DMAC (-37.96%) is better than 76.62% of its industry peers.
Industry RankSector Rank
ROA -35.78%
ROE -37.96%
ROIC N/A
ROA(3y)-35.13%
ROA(5y)-53.36%
ROE(3y)-37.27%
ROE(5y)-59.76%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DMAC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

6

2. Health

2.1 Basic Checks

DMAC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, DMAC has more shares outstanding
DMAC has a better debt/assets ratio than last year.

2.2 Solvency

DMAC has an Altman-Z score of 15.86. This indicates that DMAC is financially healthy and has little risk of bankruptcy at the moment.
DMAC has a Altman-Z score of 15.86. This is amongst the best in the industry. DMAC outperforms 90.78% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that DMAC is not too dependend on debt financing.
DMAC has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 15.86
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

DMAC has a Current Ratio of 19.27. This indicates that DMAC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 19.27, DMAC belongs to the top of the industry, outperforming 94.88% of the companies in the same industry.
DMAC has a Quick Ratio of 19.27. This indicates that DMAC is financially healthy and has no problem in meeting its short term obligations.
DMAC's Quick ratio of 19.27 is amongst the best of the industry. DMAC outperforms 94.88% of its industry peers.
Industry RankSector Rank
Current Ratio 19.27
Quick Ratio 19.27

1

3. Growth

3.1 Past

DMAC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.23%.
EPS 1Y (TTM)-19.23%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 56.88% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19%
EPS Next 2Y-18.95%
EPS Next 3Y44.28%
EPS Next 5Y56.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DMAC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DMAC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

DMAC's earnings are expected to grow with 44.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-18.95%
EPS Next 3Y44.28%

0

5. Dividend

5.1 Amount

DMAC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

DIAMEDICA THERAPEUTICS INC

NASDAQ:DMAC (4/30/2024, 7:00:02 PM)

2.53

-0.06 (-2.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap96.04M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.78%
ROE -37.96%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 19.27
Quick Ratio 19.27
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-19.23%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-19%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y